ARCA biopharma's Free Cash Flow per Share for the
three
months ended in Jun. 2024 was $-2.18.
Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $-5.71.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 40.40% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 46.80% per year.
During the past 10 years, the average Free Cash Flow per Share Growth Rate was 42.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the FCF Growth Rate using Free Cash Flow per Share data.
The historical rank and industry rank for ARCA biopharma's Free Cash Flow per Share or its related term are showing as below:
ABIO'
s 3-Year FCF Growth Rate Range Over the Past 10 Years
Min: 18.5 Med: 49.9 Max: 62.2
Current: 40.4
During the past 13 years, ARCA biopharma's highest 3-Year average Free Cash Flow per Share Growth Rate was 62.20% per year. The lowest was 18.50% per year. And the median was 49.90% per year.
ABIO's 3-Year FCF Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 10.05
vs ABIO: 40.40
ARCA biopharma Free Cash Flow per Share Historical Data
The historical data trend for ARCA biopharma's Free Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ARCA biopharma's Free Cash Flow per Share
For the Biotechnology subindustry, ARCA biopharma's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ARCA biopharma's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ARCA biopharma's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where ARCA biopharma's Price-to-Free-Cash-Flow falls into.
ARCA biopharma Free Cash Flow per Share Calculation
Free Cashflow per Share is the amount of Free Cashflow per outstanding share of the company's stock.
Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company.
Note: GuruFocus does not calculate Free Cash Flow Per Share when Capital Expenditure is 0.
ARCA biopharma's Free Cash Flow Per Share for the fiscal year that ended in Dec. 2023 is calculated as
Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.71
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARCA biopharma (NAS:ABIO) Free Cash Flow per Share Explanation
Free Cash Flow is very close to Warren Buffett's definition of Owner's Earnings, except that in Warren Buffett's Owner's Earnings, the spending for Property, Plant, and Equipment is only for maintenance (replacement), while in the Free Cash Flow calculation, the cost of new Property, Plant, and Equipment due to business expansion is also deducted. There, Free Cash Flow is more conservative than Owner's Earnings.
In Don Yacktman's calculation of forward rate of return, he uses Free Cash Flow for the calculation. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation.
This is what Yacktman said in his March 2012 interview - when the S&P 500 was at 1400:
If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.
The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).
For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is because research shows that five years is the length of the typical business cycle.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Free Cash Flow within a report period can be affected by management's decisions of capital spending. Therefore, it is important to look at long term when it comes to Free Cash Flow.
ARCA biopharma Free Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of ARCA biopharma's Free Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ABIO has been successfully added to your 